<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-10T19:05:12Z</responseDate>
  <request identifier="oai:figshare.com:article/33966364" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33966364</identifier>
        <datestamp>2026-09-22T16:32:24Z</datestamp>
        <setSpec>category_24733</setSpec>
        <setSpec>category_24739</setSpec>
        <setSpec>category_24748</setSpec>
        <setSpec>category_24850</setSpec>
        <setSpec>category_24853</setSpec>
        <setSpec>category_24871</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Impact of genetic Sigma1 deficiency on development of status epilepticus and</dc:title>
          <dc:creator>Heidrun Potschka (14789275)</dc:creator>
          <dc:subject>Central nervous system</dc:subject>
          <dc:subject>Neurology and neuromuscular diseases</dc:subject>
          <dc:subject>Neurosciences not elsewhere classified</dc:subject>
          <dc:subject>Basic pharmacology</dc:subject>
          <dc:subject>Clinical pharmacology and therapeutics</dc:subject>
          <dc:subject>Pharmacology and pharmaceutical sciences not elsewhere classified</dc:subject>
          <dc:subject>antiseizure medication</dc:subject>
          <dc:subject>temporal lobe epilepsy</dc:subject>
          <dc:subject>intrahippocampal kainate model</dc:subject>
          <dc:subject>target validation</dc:subject>
          <dc:subject>Sigma-1</dc:subject>
          <dc:description>&lt;table&gt;&lt;tr&gt;&lt;td&gt;&lt;p dir="ltr"&gt;Sigma-1 is an atypical receptor protein that modulates neuronal excitability and cellular stress responses, making it a promising target for epilepsy management. The intrahippocampal kainate model allows assessment of the impact of Sigma-1 deficiency on the induction of status epilepticus and the subsequent development of spontaneous recurrent seizures in wild-type in comparison to Sigma-1-knockout mice. Kainate was slowly injected into the CA1 region of the right hippocampus under anesthesia and multimodal analgesia. During the same stereotactic surgical procedure, animals received a depth electrode implant in the CA1 region. The severity of induced status epilepticus was continuously monitored by electrographic recordings. To obtain additional information about behavioral and/or motor patterns (incl. immobility, head nodding, circling, and intermittent generalized convulsive seizures) during limbic status epilepticus, videos were recorded in parallel. During the following weeks, telemetric EEG recordings were conducted to assess the development of spontaneous recurrent seizures. The frequency and duration of electrographic seizures were determined. Videos were recorded in parallel to capture occasional behavioral seizures.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p&gt;&lt;/p&gt;</dc:description>
          <dc:date>2026-09-22T16:32:24Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.6084/m9.figshare.33966364.v1</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Impact_of_genetic_Sigma1_deficiency_on_development_of_status_epilepticus_and/33966364</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
